Korea's CJ CheilJedang and Japan's RaQualia Pharma Partner For Gastrointestinal Therapies
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's CJ CheilJedang signed a memorandum of understanding and subsequently a licensing agreement with Japan's RaQualia Pharma to establish a strategic alliance for the latter's innovative gastrointestinal therapies